Relay Therapeutics is a clinical-stage precision medicine company that leverages computational and experimental approaches to discover and develop next-generation protein motion-based therapies. The company focuses on understanding protein motion and conformational changes to design targeted treatments for cancer and other serious diseases.
Founded in 2015 by a team of leading computational biologists and drug discovery experts, Relay went public on NASDAQ in 2020, raising significant capital to advance its pipeline. The company's platform combines physics-based computational modeling with experimental biology to identify novel drug targets and design small molecule therapeutics. Relay has partnerships with major pharmaceutical companies and continues to advance multiple programs through clinical development in oncology.
Relay Therapeutics has received investment from 3 venture capital firms.
Clinical-stage precision medicine company using computational approaches to develop protein motion-based therapies for cancer.
Relay Therapeutics has received investment from Atlas Venture, Roche Venture Fund, Section 32. These venture capital firms and investors provide both capital and strategic support.
Relay Therapeutics operates in the Biotech sector. Clinical-stage precision medicine company using computational approaches to develop protein motion-based therapies for cancer.
